1. Name and Address of Reporting Person
   Gosebruch Henry O
   1 N. WAUKEGAN ROAD
   NORTH CHICAGO IL 60064

2. Issuer Name and Ticker or Trading Symbol
   AbbVie Inc. [ ABBV ]

3. Date of Earliest Transaction (Month/Day/Year)
   02/20/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer
   Director
   EVP, Chief Strategy Officer

6. Individual or Joint/Group Filing (Check Applicable Line)
   X Form filed by One Reporting Person
   Form filed by More than One Reporting Person

---

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 3 and 4)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock, $0.01 par value</td>
<td>02/20/2020</td>
<td>A</td>
<td>$32,524(1)</td>
<td>$0</td>
<td>78,287</td>
<td>D</td>
</tr>
<tr>
<td>Common stock, $0.01 par value</td>
<td>02/20/2020</td>
<td>A</td>
<td>$11,730(2)</td>
<td>$0</td>
<td>90,017</td>
<td>D</td>
</tr>
<tr>
<td>Common stock, $0.01 par value</td>
<td>02/20/2020</td>
<td>A</td>
<td>$6,555(3)</td>
<td>$0</td>
<td>96,572</td>
<td>D</td>
</tr>
<tr>
<td>Common stock, $0.01 par value</td>
<td>02/20/2020</td>
<td>A</td>
<td>$7,972(4)</td>
<td>$0</td>
<td>104,544</td>
<td>D</td>
</tr>
<tr>
<td>Common stock, $0.01 par value</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30,000(5)</td>
<td>I In trust</td>
</tr>
<tr>
<td>Common stock, $0.01 par value</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2,276(6)</td>
<td>I Profit sharing trust</td>
</tr>
</tbody>
</table>

---

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>02/20/2020</td>
<td>A</td>
<td>96,563</td>
<td>02/20/2021</td>
<td>02/19/2030</td>
<td>Common Stock</td>
<td>96,563</td>
<td>0</td>
<td>96,563</td>
<td>D</td>
</tr>
</tbody>
</table>

### Explanation of Responses:
1. Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie’s Board of Directors. The shares will be issued to the reporting person on February 28, 2020.
2. Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie’s Board of Directors. The shares will be issued to the reporting person on February 28, 2020.
3. Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie’s Board of Directors. The shares will be issued to the reporting person on February 28, 2020.
4. Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie’s Board of Directors. The shares will be issued to the reporting person on February 28, 2020.
5. The reporting person is trustee of a trust established for the benefit of his children. The reporting person disclaims beneficial ownership of all securities held by the trust.
7. Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of $21,188 on February 20, 2021, $21,188 on February 20, 2022, and $21,187 on February 20, 2023.

**Signature of Reporting Person**

---

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.